How to use digital platforms?
Keywords:
diabetes, tecnologyAbstract
Digital platforms consist of support tools that provide structured, objective and quality information for both the patient and the health team. Its purpose is to be able to articulate, facilitate and complement more individualized attention, facilitating interaction, communication and exchange. These may include glucose monitoring and management applications such as My Sugr or Librelink that receive data from the glucometer and/or sensor and allow patients to record relevant data such as food intake, physical activity and medications, helping them identify patterns for adjustments in treatment Other apps can provide recommendations, nutritional analysis and reminders that impact adherence and international consensuses have been developed to validate them with available evidence on their safety and effectiveness, although it is still limited.
Regarding continuous glucose monitoring, there are several virtual platforms such as Libreview for readings from the Freestyle libre device or Clarity for Dexcom, which provide real-time readings and trend graphs and in the case of continuous insulin infusers, the Carelink platforms for downloading data from Medtronic infusers, Smartpix for downloading Accuchek infusers, both Combo and Solo, and in the case of Medtrum infusers, the EasyView Pro platforms for professionals and EasyView Personal for patients.
To use them, it is important to learn how to read the reports that will provide insight and analysis of insulin infusion, glucose trends and recorded events and thus adjust treatment and monitor programming to adapt treatment to changing needs. Many platforms provide data in real time, being able to define time in range, glucose management indicator, coefficient of variation and the evaluation of the use of counting and exercise in the glycemic pattern. There is evidence such as the PDM-Provalue study of the improvement in control and the favorable impact in the treatment of platforms and apps, such as the RDCP management platform
Today, platforms for virtual consultations and online education have also proliferated, making telemedicine a valuable exchange tool for diabetes care teams.
Our challenge as specialists together with our patient is to move from data collection to the generation of information for decision making and advanced analysis that will evolve with artificial intelligence.
References
I. Fleming GA, Petrie JR, Bergenstal RM, Holl RW, Peters AL, Heinemann L. Diabetes digital App technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetes Care. 2020 Jan;43(1):250-260.
II. Fagherazzi G, Ravaud P. Digital diabetes: perspectives for diabetes prevention, management and research. Diabetes MEtab. 2019;45(4):322-329.
III. Battelino T. Evolution of diabetes technology. Endocrinol Metab Clin North Am. 2020 Mar;49(1):1-18.
IV. Kulzer B, Daenschel W, Daenschel I, et al. Integrated personalized diabetes management improves glycemic control in patients with insulin-treated type 2 diabetes: Results of the PDM-ProValue study program. Diabetes Res Clin Pract. 2018;144:200-212.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 on behalf of the authors. Reproduction rights: Argentine Society of Diabetes
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
